

## **EIS ECZACIBASI PHARMACEUTICAL AND INDUSTRIAL INVESTMENT CO.**

**Date: 26.05.2011**

By acquiring Mol-Image, which is active in research, development, innovation and manufacturing in molecular medicine as an R&D and advanced technology company, Eczacıbaşı-Monrol has taken a further step toward its targets in the field of nuclear medicine.

Thanks to the synergy to be created by such acquisition, it is intended that some medicinal active ingredients and consumables currently used by Eczacıbaşı-Monrol as well as new products planned to be manufactured in the future are developed and manufactured by Mol-Image in an environment in conformity with the good manufacturing practice in the European Union countries and the United States. With this synergy, it is also aimed at place on the market all over the world especially including Turkey and Europe using the sales channel of Eczacıbaşı-Monrol the innovative devices and equipment developed by Mol-Image which can be used in nuclear medicine.

Speaking at the signature ceremony held on the occasion of the acquisition, Dr. Erdal Karamercan, the CEO of Eczacıbaşı Holding, stated that they attached strategic priority to innovation which they consider as a driving force for growth, added “We believe that our innovation studies have now reached the radical innovation phase. While we are conducting studies to achieve a competitive edge and create new opportunities in our existing fields of business, we are also investing toward the radical innovation. One of these initiatives is the acquisition of Mol-Image by Eczacıbaşı-Monrol”.

Karamercan went on to say, “Mol-Image, which is active in R&D and innovation studies in nuclear pharmaceuticals, will certainly add to our power and convey the leading position of Eczacıbaşı-Monrol, continuing its growth in the local and overseas markets, to the target overseas market in addition to Turkey”.

In his ceremonial speech, Dr. Şükrü Bozluoğlu, the Chairman of the Board of Directors of Bozlu Holding and Mol-Image pointed out that, thanks to that acquisition, Eczacıbaşı-Monrol would leave its position where it follows the new developments in nuclear medicine and it would now become the pioneer of such developments.

Stating that this important step taken by Eczacıbaşı-Monrol would enable that new molecular imaging technologies developed in the rest of the world are offered simultaneously in Turkish market, Dr Şükrü said “This will certainly make it possible for make a healthier planning of diagnostic and treatment process of certain diseases which cannot be early detected for the time being”.

### **Mol-Image**

Moleküler Görüntüleme A.Ş. (Mol-Image), one of the group companies of Bozlu Holding, was established in 2002 for the purpose of carry out R&D studies in nuclear medicine, determine new requirements through studies for implementation and develop new devices, chemicals, radiopharmaceuticals and radiation protection equipment. Starting its R&D activities at its existing building on 1 July 2008, Mol-Image continues its activities aiming at developing and manufacturing the molecular synthesis, mecatronic equipment and radiation-protection equipment at its facilities located on an area of 1500 sqm at TUBITAK Marmara Research Center Campus, Technology Free Zone.